Evidence map›Paper›PMID 36552276›Full record

ReviewBiology2022

The Efficacy and Safety of Rituximab in ANCA-Associated Vasculitis: A Systematic Review.

Mohammad Amin Habibi, Samira Alesaeidi, Mohadeseh Zahedi, Samin Hakimi Rahmani, Seyed Mohammad Piri, Soheil Tavakolpour

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 5 pooled it
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 5 syntheses or guidelines pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Mohammad Amin HabibiClinical Research Development Center, Qom University of Medical Sciences, Qom 3719964797, Iran.ORCID 0000-0001-7600-6925
Samira AlesaeidiRheumatology Research Center, Tehran University of Medical Sciences, Tehran P.O. Box 982188220065, Iran.
Mohadeseh ZahediClinical Research Development Center, Qom University of Medical Sciences, Qom 3719964797, Iran.
Samin Hakimi RahmaniClinical Research Development Center, Qom University of Medical Sciences, Qom 3719964797, Iran.
Seyed Mohammad PiriSina Trauma and Surgery Research Center, Tehran University of Medical Sciences, Tehran P.O. Box 982166757001, Iran.
Soheil TavakolpourDana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
Qom University of Medical Science and Health Services · IRTehran University of Medical Sciences · IRHarvard University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

immunopharmacologyMPO-associated vasculitisPR3-associated vasculitisrituximabsmall vessel vasculitiswegner

Identifiers

PMID36552276
PMCPMC9774915
OpenAlexW4311720843

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.